Contraindications: Anavar 50 must not be used by individuals with active hepatic impairment, diagnosed prostate or breast carcinoma, polycythaemia vera, or nephrotic syndrome. Women of childbearing potential should not use this product. Concurrent use with oral anticoagulants (warfarin) requires physician oversight, as Oxandrolone potentiates anticoagulant effect — an interaction particularly relevant in stacking protocols where multiple agents are running simultaneously.
Side Effects: Hepatotoxicity risk is present with any C-17α alkylated oral compound; at 50 mg/day, hepatic enzyme elevation (ALT/AST) is a known monitoring target. Endogenous testosterone suppression occurs dose-dependently and is compounded when Oxandrolone is stacked with exogenous testosterone. Androgenic effects including scalp-hair thinning and sebum overproduction may occur in genetically predisposed individuals. Lipid profile disruption — specifically HDL suppression — is documented with Oxandrolone and should be tracked across a full stack cycle.
Monitoring: Obtain baseline bloodwork before stack initiation: liver enzymes (ALT, AST, GGT), full lipid panel (LDL, HDL, triglycerides), haematocrit, and total testosterone. Repeat at mid-cycle (approximately week 6) and at end-of-stack. In multi-compound protocols, distinguish compound-specific side effects by staggering bloodwork timing relative to individual compound additions where feasible.
PCT: Oxandrolone suppresses the hypothalamic-pituitary-gonadal axis; full SERM-based PCT (Clomiphene or Tamoxifen, per standard protocol) is required after any Oxandrolone-containing stack. Allow sufficient washout of all stack components before PCT initiation — Oxandrolone's elimination occurs within 48 hours of last dose, but longer-estered testosterone partners require ester-specific washout periods before the HPG axis is accessible for SERM stimulation.
Lab Tested
